New York State Common Retirement Fund
AVTX icon

New York State Common Retirement Fund’s Avalo Therapeutics AVTX Stock Holding History

New York State Common Retirement Fund’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Hold
0
– – – 3237
2022
Q3 		– Hold
0
– – – 3277
2022
Q2 		– Sell
-8
Closed -$10.7K – 3473
2022
Q1 		$16K Hold
8
– – ﹤0.01% 3298
2021
Q4 		$38K Hold
8
– – ﹤0.01% 3263
2021
Q3 		$48K Hold
8
– – ﹤0.01% 3246
2021
Q2 		$72K Hold
8
– – ﹤0.01% 3244
2021
Q1 		$66K Buy
8
+7
+700% +$66.1K ﹤0.01% 3160
2020
Q4 		$9K Hold
1
– – ﹤0.01% 3256
2020
Q3 		$8K Hold
1
– – ﹤0.01% 3218
2020
Q2 		$9K Hold
1
– – ﹤0.01% 3200
2020
Q1 		$8K Sell
1
-7
-88% -$74K ﹤0.01% 3153
2019
Q4 		$118K Hold
8
– – ﹤0.01% 2958
2019
Q3 		$72K Hold
8
– – ﹤0.01% 3106
2019
Q2 		$119K Buy
+8
New +$121K ﹤0.01% 3040

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

New York State Common Retirement Fund's AVTX Position: Q4 2022 in Review

New York State Common Retirement Fund held its Avalo Therapeutics (AVTX) position steady in Q4 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3237.

New York State Common Retirement Fund first reported a position in AVTX in Q2 2019 and has held it in 12 quarters since. The position peaked at $119K in Q2 2019. 19 funds tracked by Wall St. Rank hold AVTX as of Q4 2022.

  • New York State Common Retirement Fund held 0 shares of Avalo Therapeutics worth $0 as of Q4 2022.
  • New York State Common Retirement Fund left its Avalo Therapeutics share count unchanged in Q4 2022.
  • Avalo Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q4 2022, its #3237 holding.
  • New York State Common Retirement Fund first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 12 quarters since.
  • New York State Common Retirement Fund's Avalo Therapeutics position peaked at $119K in Q2 2019.
  • 19 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2022.

Based on New York State Common Retirement Fund's 13F filing for Q4 2022, filed 30 Jan 2023.